Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 13.05B | 13.93B | 12.78B | 11.55B | 11.19B |
Gross Profit | 7.92B | 8.47B | 7.70B | 7.25B | 7.19B |
EBITDA | 1.37B | 2.04B | 1.87B | 1.42B | 2.13B |
Net Income | -53.72M | 581.85M | 611.78M | 508.48M | 1.14B |
Balance Sheet | |||||
Total Assets | 18.84B | 20.04B | 20.96B | 20.28B | 17.22B |
Cash, Cash Equivalents and Short-Term Investments | 1.60B | 1.45B | 2.30B | 2.40B | 1.83B |
Total Debt | 9.36B | 9.22B | 9.67B | 9.48B | 6.17B |
Total Liabilities | 13.03B | 13.75B | 14.82B | 14.40B | 11.02B |
Stockholders Equity | 5.81B | 6.30B | 6.14B | 5.89B | 6.20B |
Cash Flow | |||||
Free Cash Flow | 1.25B | 1.01B | 1.37B | 1.78B | 1.43B |
Operating Cash Flow | 1.35B | 1.10B | 1.47B | 1.89B | 1.53B |
Investing Cash Flow | 895.00K | -52.07M | -104.88M | -4.01B | -1.24B |
Financing Cash Flow | -1.07B | -1.99B | -1.49B | 2.77B | -687.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $7.59B | 21.96 | -0.91% | 0.85% | -8.10% | -108.48% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
$1.33B | 40.93 | 7.71% | 1.79% | ― | ― | ||
72 Outperform | HK$13.39B | 16.70 | 15.77% | 6.21% | 4.68% | -14.34% | |
71 Outperform | HK$7.18B | 37.19 | 5.15% | 1.40% | 3.95% | -42.81% | |
66 Neutral | HK$3.70B | 14.47 | 4.14% | 2.88% | -1.56% | 30.87% | |
64 Neutral | HK$9.23B | 36.07 | 2.39% | ― | ― |
Health and Happiness (H&H) International Holdings Limited reported a mid-single-digit increase in total revenue for the first half of 2025, driven by growth across all business segments. The Adult Nutrition and Care segment saw significant growth in mainland China and other markets, while the Baby Nutrition and Care segment experienced a resurgence in infant milk formula sales. Despite challenges in the pediatric probiotic sector, the Pet Nutrition and Care segment benefited from trends in pet nutrition and humanization. The company’s strategic focus on e-commerce and market expansion has bolstered its industry position.
The most recent analyst rating on (HK:1112) stock is a Buy with a HK$13.10 price target. To see the full list of analyst forecasts on Health and Happiness (H&H) International Holdings stock, see the HK:1112 Stock Forecast page.
Health and Happiness (H&H) International Holdings Limited has outlined the terms of reference for its Nomination Committee, which was established to oversee the structure and composition of the company’s board of directors. The committee is tasked with ensuring the board’s alignment with corporate strategy by reviewing its size, skills, and diversity, and making recommendations for potential new board members. This initiative is expected to enhance the company’s governance and strategic direction, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1112) stock is a Buy with a HK$13.10 price target. To see the full list of analyst forecasts on Health and Happiness (H&H) International Holdings stock, see the HK:1112 Stock Forecast page.
Health and Happiness (H&H) International Holdings Limited held its Annual General Meeting on May 12, 2025, where all proposed resolutions were passed by poll. Key resolutions included the adoption of financial statements, declaration of a final dividend, re-election of directors, re-appointment of auditors, and granting of mandates to the board for share issuance and repurchase. These decisions reflect the company’s strategic direction and commitment to shareholder value, potentially impacting its market positioning and operational capabilities.
The most recent analyst rating on (HK:1112) stock is a Buy with a HK$13.10 price target. To see the full list of analyst forecasts on Health and Happiness (H&H) International Holdings stock, see the HK:1112 Stock Forecast page.
Health and Happiness (H&H) International Holdings Limited reported a 10.4% increase in total revenue for the first quarter of 2025, driven by a strong recovery in mainland China and growth in core markets. The company’s infant milk formula business led the growth with a 46.9% increase, contributing significantly to the Baby Nutrition and Care segment’s 25.3% rise. The Adult Nutrition & Care and Pet Nutrition & Care segments also saw growth, supported by high-margin nutritional supplements which made up 65.1% of total revenue. The company maintained a healthy liquidity position with a cash balance of RMB1.4 billion.